Is Evotec SE (EVO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 40.3% / 30% | 36.1% / 30% | 19.9% / 30% | 0.31% / 5% | ✗ NOT HALAL |
| DJIM | 40.3% / 33% | 36.1% / 33% | 19.9% / 33% | 0.31% / 5% | ✗ NOT HALAL |
| MSCI | 23.2% / 33% | 20.7% / 33% | 11.4% / 33% | 0.31% / 5% | ✓ HALAL |
| S&P | 40.3% / 33% | 36.1% / 33% | 19.9% / 33% | 0.31% / 5% | ✗ NOT HALAL |
| FTSE | 23.2% / 33% | 20.7% / 33% | 11.4% / 50% | 0.31% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 10.8% | |
| Operating Margin | -26.6% | |
| Net Margin | -21.0% | |
| Return on Equity (ROE) | -18.0% | |
| Return on Assets (ROA) | -2.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $18M |
| Free Cash Flow | -$114M |
| Total Debt | $444M |
| Debt-to-Equity | 60.6 |
| Current Ratio | 2.1 |
| Total Assets | $1.9B |
Price & Trading
| Last Close | $2.46 |
| 50-Day MA | $3.19 |
| 200-Day MA | $3.54 |
| Avg Volume | 138K |
| Beta | 1.1 |
|
52-Week Range
$2.31
| |
About Evotec SE (EVO)
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Evotec SE (EVO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Evotec SE is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Evotec SE's debt ratio?
Evotec SE's debt ratio is 40.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 23.2%.
What are Evotec SE's key financial metrics?
Evotec SE has a market capitalization of $867M, and revenue of $797M. The company maintains a gross margin of 10.8% and a net margin of -21.0%. Return on equity stands at -18.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.